Given the fact that FAP proved to be a reliable marker of activated CAF, and that high expression of FAP almost exclusively occurs in invasive carcinomas but not in adenomas or non-neoplastic, non-inflammatory tissue, FAP has the potential to emerge as a powerful target for new diagnostic and therapeutic concepts in CRC. The gene discussed is FAP; the disease is colorectal carcinoma.